Metabolic Dysfunction‐Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda

ABSTRACT Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus‐driven research and action agenda to address MASLD within the MENA region. Methods Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 n  = 112, R2 n  = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda. Results The consensus‐built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., ‘agree’ + ‘somewhat agree’) increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research ( n  = 30) and action ( n  = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non‐invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers. Conclusions This region‐specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.